Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
143 hedge funds and large institutions have $909M invested in Cymabay Therapeutics in 2019 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 49 increasing their positions, 35 reducing their positions, and 15 closing their positions.
98% more capital invested
Capital invested by funds: $458M → $909M (+$451M)
90% more call options, than puts
Call options by funds: $1.62M | Put options by funds: $852K
80% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 15
40% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 35
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
9% more funds holding
Funds holding: 131 → 143 (+12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$19.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$19.3M |
| 3 |
PA
Perceptive Advisors
New York
|
+$18.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$14.7M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
+$12.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$10.6M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$8.98M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$6.5M |
| 4 |
NC
Nexthera Capital
New York
|
-$5.37M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.52M |
CBAY Hedge Fund Activity: Q1 2019 in Review
143 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2019, worth a combined $909M — up 98% from $458M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new CBAY positions and 15 closed out — a net gain of 12 holders — while 49 added to existing stakes and 35 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $19.9M. The largest seller was Deerfield Management, exiting entirely with an estimated $10.6M sold.
- 143 institutional investors held Cymabay Therapeutics (CBAY) as of Q1 2019, up from 131 in Q4 2018.
- Funds reported $909M of Cymabay Therapeutics stock for Q1 2019, up 98% quarter-over-quarter.
- 27 funds opened new Cymabay Therapeutics positions in Q1 2019 and 15 closed out, a net change of +12 holders.
- The largest Cymabay Therapeutics buyer in Q1 2019 was OrbiMed, an estimated $19.9M added.
- The largest Cymabay Therapeutics seller in Q1 2019 was Deerfield Management, an estimated $10.6M sold.
Based on aggregated 13F filings for Q1 2019.